Thromb Haemost 2022; 122(11): 1911-1920
DOI: 10.1055/a-1863-2052
Stroke, Systemic or Venous Thromboembolism

Joint Effect of Multiple Prothrombotic Genotypes and Mean Platelet Volume on the Risk of Incident Venous Thromboembolism

Lisa Jakobsen
1   Department of Clinical Medicine, Thrombosis Research Center, UiT-The Arctic University of Norway, Tromsø, Norway
,
1   Department of Clinical Medicine, Thrombosis Research Center, UiT-The Arctic University of Norway, Tromsø, Norway
2   Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
,
Sigrid K. Brækkan
1   Department of Clinical Medicine, Thrombosis Research Center, UiT-The Arctic University of Norway, Tromsø, Norway
2   Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
,
John-Bjarne Hansen
1   Department of Clinical Medicine, Thrombosis Research Center, UiT-The Arctic University of Norway, Tromsø, Norway
2   Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
,
Vânia M. Morelli
1   Department of Clinical Medicine, Thrombosis Research Center, UiT-The Arctic University of Norway, Tromsø, Norway
2   Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
› Author Affiliations
Funding Thrombosis Research Center (TREC) was supported by an independent grant from Stiftelsen Kristian Gerhard Jebsen (2014–2020). T.F. is supported by the Northern Norway Regional Health Authority.


Abstract

Background A high mean platelet volume (MPV), a marker of increased platelet reactivity, is a risk factor for venous thromboembolism (VTE). Whether established prothrombotic single nucleotide polymorphisms (SNPs) further increase the VTE risk in subjects with high MPV because of biological interaction remains unknown.

Aim To investigate the joint effect of high MPV and prothrombotic genotypes, comprising a 5-SNP genetic risk score (GRS), on the risk of VTE in a population-based case–cohort.

Methods Incident VTE cases (n = 653) and a subcohort (n = 1,774) were derived from the Tromsø Study (1994–2012). DNA was genotyped for rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2036914 (F11), and rs2066865 (FGG). Hazard ratios (HRs) for VTE with 95% confidence intervals (CIs) were estimated according to predefined MPV-strata (<8.5, 8.5–9.5, ≥9.5 fL) and number of risk alleles for each individual SNP and the GRS (0–1, 2–3, ≥4 risk alleles) in models adjusted for age, sex, body mass index, and platelet count.

Results The combination of high MPV and risk alleles, either as individual SNPs or the GRS, had an additive effect on VTE risk. Compared with subjects with MPV <8.5 fL and 0–1 risk allele, those with high MPV (≥9.5 fL) and ≥4 risk alleles had HRs of 2.80 (95% CI: 1.77-4.43) for overall VTE and 4.60 (95% CI: 2.20–9.60) for unprovoked events, respectively, but there was no supra-additive effect on risk estimates.

Conclusion The combination of high MPV and prothrombotic genotypes had an additive effect on VTE risk, suggesting there is no biological interaction between these risk factors in the pathogenesis of VTE.

Supplementary Material



Publication History

Received: 04 January 2022

Accepted: 25 May 2022

Accepted Manuscript online:
26 May 2022

Article published online:
31 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
  • 2 Raskob GE, Angchaisuksiri P, Blanco AN. et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 (11) 2363-2371
  • 3 Schulman S, Lindmarker P, Holmström M. et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (04) 734-742
  • 4 Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev 2014; 28 (06) 221-226
  • 5 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353 (9159): 1167-1173
  • 6 Cushman M, Tsai AW, White RH. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117 (01) 19-25
  • 7 Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost 2010; 8 (01) 157-162
  • 8 Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica 2010; 95 (02) 270-275
  • 9 Rezende SM, Lijfering WM, Rosendaal FR, Cannegieter SC. Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk. Haematologica 2014; 99 (01) 194-200
  • 10 Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Red cell distribution width is associated with incident venous thromboembolism (VTE) and case-fatality after VTE in a general population. Thromb Haemost 2015; 113 (01) 193-200
  • 11 Zöller B, Melander O, Svensson P, Engström G. Red cell distribution width and risk for venous thromboembolism: a population-based cohort study. Thromb Res 2014; 133 (03) 334-339
  • 12 Handtke S, Thiele T. Large and small platelets-(When) do they differ?. J Thromb Haemost 2020; 18 (06) 1256-1267
  • 13 Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005; 59 (08) 981-982
  • 14 Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des 2011; 17 (01) 47-58
  • 15 Johnson AD. The genetics of common variation affecting platelet development, function and pharmaceutical targeting. J Thromb Haemost 2011; 9 (Suppl. 01) 246-257
  • 16 Eicher JD, Lettre G, Johnson AD. The genetics of platelet count and volume in humans. Platelets 2018; 29 (02) 125-130
  • 17 de Haan HG, Bezemer ID, Doggen CJ. et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012; 120 (03) 656-663
  • 18 Morelli VM, de Visser MC, van Tilburg NH. et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007; 97 (04) 534-541
  • 19 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369 (6475): 64-67
  • 20 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-3703
  • 21 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106 (13) 4176-4183
  • 22 Li Y, Bezemer ID, Rowland CM. et al. Genetic variants associated with deep vein thrombosis: the F11 locus. J Thromb Haemost 2009; 7 (11) 1802-1808
  • 23 Evensen LH, Arnesen CAL, Rosendaal FR. et al. The risk of venous thromboembolism attributed to established prothrombotic genotypes. Thromb Haemost 2022; 122 (07) 1221-1230
  • 24 Rothman K. ed. Measuring interactions. In: Epidemiology: An Introduction. Oxford: Oxford University Press; 2002: 198-210
  • 25 Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: the Tromso study. Int J Epidemiol 2012; 41 (04) 961-967
  • 26 Braekkan SK, Borch KH, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB. Body height and risk of venous thromboembolism: the Tromsø study. Am J Epidemiol 2010; 171 (10) 1109-1115
  • 27 Horvei LD, Braekkan SK, Smith EN. et al. Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study. J Thromb Haemost 2018; 16 (01) 83-89
  • 28 Edvardsen MS, Hansen ES, Hindberg K. et al. Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. Blood 2021; 138 (22) 2269-2277
  • 29 Braekkan SK, Siegerink B, Lijfering WM, Hansen JB, Cannegieter SC, Rosendaal FR. Role of obesity in the etiology of deep vein thrombosis and pulmonary embolism: current epidemiological insights. Semin Thromb Hemost 2013; 39 (05) 533-540
  • 30 Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005; 20 (07) 575-579
  • 31 Kovács S, Csiki Z, Zsóri KS, Bereczky Z, Shemirani AH. Characteristics of platelet count and size and diagnostic accuracy of mean platelet volume in patients with venous thromboembolism. A systematic review and meta-analysis. Platelets 2019; 30 (02) 139-147
  • 32 Riedl J, Kaider A, Reitter EM. et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2014; 111 (04) 670-678
  • 33 Rupa-Matysek J, Gil L, Barańska M, Dytfeld D, Komarnicki M. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget 2018; 9 (30) 21190-21200
  • 34 Whitfield JB, Martin NG. Genetic and environmental influences on the size and number of cells in the blood. Genet Epidemiol 1985; 2 (02) 133-144
  • 35 Ross DW, Ayscue LH, Watson J, Bentley SA. Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation. Am J Clin Pathol 1988; 90 (03) 262-267
  • 36 Morange PE, Suchon P, Trégouët DA. Genetics of venous thrombosis: update in 2015. Thromb Haemost 2015; 114 (05) 910-919
  • 37 Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 1969; 48 (06) 1083-1087
  • 38 Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size as a determinant of platelet function. J Lab Clin Med 1983; 101 (02) 205-213
  • 39 Handtke S, Steil L, Palankar R. et al. Role of platelet size revisited-function and protein composition of large and small platelets. Thromb Haemost 2019; 119 (03) 407-420
  • 40 Brill A, Fuchs TA, Chauhan AK. et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117 (04) 1400-1407
  • 41 von Brühl ML, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (04) 819-835
  • 42 Perrella G, Nagy M, Watson SP, Heemskerk JWM. Platelet GPVI (glycoprotein VI) and thrombotic complications in the venous system. Arterioscler Thromb Vasc Biol 2021; 41 (11) 2681-2692
  • 43 Rinde LB, Morelli VM, Småbrekke B. et al. Effect of prothrombotic genotypes on the risk of venous thromboembolism in patients with and without ischemic stroke. The Tromsø Study. J Thromb Haemost 2019; 17 (05) 749-758
  • 44 Småbrekke B, Rinde LB, Evensen LH. et al. Impact of prothrombotic genotypes on the association between family history of myocardial infarction and venous thromboembolism. J Thromb Haemost 2019; 17 (08) 1363-1371
  • 45 Clarke R, Shipley M, Lewington S. et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150 (04) 341-353
  • 46 Kang HM, Sul JH, Service SK. et al. Variance component model to account for sample structure in genome-wide association studies. Nat Genet 2010; 42 (04) 348-354
  • 47 Solomon T, Smith EN, Matsui H. et al; INVENT Consortium. Associations between common and rare exonic genetic variants and serum levels of 20 cardiovascular-related proteins: the Tromsø Study. Circ Cardiovasc Genet 2016; 9 (04) 375-383